Previous Close | $376.58 |
Intrinsic Value | $11.16 |
Upside potential | -97% |
Data is not available at this time.
HCA Healthcare, Inc. operates as a leading for-profit healthcare provider in the U.S., delivering a comprehensive range of medical services through its network of hospitals, outpatient centers, and physician clinics. The company generates revenue primarily through patient care services, including inpatient and outpatient treatments, emergency care, and surgical procedures. Its vertically integrated model allows for cost efficiencies and scale advantages, positioning HCA as a dominant player in high-growth urban and suburban markets. HCA differentiates itself through advanced clinical capabilities, strategic partnerships with physicians, and investments in technology to enhance patient outcomes. The company’s market leadership is reinforced by its focus on high-acuity services, which command premium pricing and drive margin expansion. Operating in a highly regulated and competitive industry, HCA leverages its scale to negotiate favorable payer contracts while maintaining a reputation for quality care. Its diversified geographic footprint mitigates regional risks and supports steady demand, underpinned by demographic trends favoring healthcare utilization.
HCA reported $70.6 billion in revenue for FY 2024, reflecting its ability to monetize high-acuity services and manage costs effectively. Net income stood at $5.8 billion, with diluted EPS of $22, demonstrating robust profitability. Operating cash flow of $10.5 billion underscores strong cash generation, though capital expenditures of $4.9 billion indicate significant reinvestment in facilities and technology to sustain growth.
The company’s earnings power is evident in its consistent margin performance, driven by operational discipline and pricing leverage. HCA’s capital efficiency is supported by its ability to generate high returns on invested capital, though its debt-heavy capital structure necessitates careful liquidity management. The balance between growth investments and shareholder returns remains a key focus.
HCA’s balance sheet shows $1.9 billion in cash and equivalents against $45.2 billion in total debt, reflecting a leveraged but manageable position. The company’s strong cash flow generation provides ample coverage for debt servicing and strategic investments. Financial health is further supported by its ability to access capital markets at favorable terms.
HCA has demonstrated steady growth through organic volume increases and selective acquisitions. The company’s dividend policy, with a $2.67 per share payout, signals confidence in sustained cash flow generation. Future growth is expected to be driven by demographic tailwinds and operational efficiencies, though regulatory pressures remain a monitorable risk.
Market expectations for HCA reflect its leadership position and growth prospects, with valuations factoring in its ability to maintain margins amid cost pressures. The stock’s performance is closely tied to healthcare utilization trends and reimbursement dynamics, with investors pricing in moderate earnings growth.
HCA’s strategic advantages include its scale, clinical expertise, and geographic diversification. The outlook remains positive, supported by aging demographics and increasing healthcare demand. However, regulatory changes and labor cost inflation could pose challenges. The company’s focus on technology and efficiency initiatives positions it well for long-term success.
10-K, investor presentations
show cash flow forecast
Fiscal year | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | |
INCOME STATEMENT | ||||||||||||||||||||||||||
Revenue growth rate, % | NaN | |||||||||||||||||||||||||
Revenue, $ | NaN | |||||||||||||||||||||||||
Variable operating expenses, $m | NaN | |||||||||||||||||||||||||
Fixed operating expenses, $m | NaN | |||||||||||||||||||||||||
Total operating expenses, $m | NaN | |||||||||||||||||||||||||
Operating income, $m | NaN | |||||||||||||||||||||||||
EBITDA, $m | NaN | |||||||||||||||||||||||||
Interest expense (income), $m | NaN | |||||||||||||||||||||||||
Earnings before tax, $m | NaN | |||||||||||||||||||||||||
Tax expense, $m | NaN | |||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
BALANCE SHEET | ||||||||||||||||||||||||||
Cash and short-term investments, $m | NaN | |||||||||||||||||||||||||
Total assets, $m | NaN | |||||||||||||||||||||||||
Adjusted assets (=assets-cash), $m | NaN | |||||||||||||||||||||||||
Average production assets, $m | NaN | |||||||||||||||||||||||||
Working capital, $m | NaN | |||||||||||||||||||||||||
Total debt, $m | NaN | |||||||||||||||||||||||||
Total liabilities, $m | NaN | |||||||||||||||||||||||||
Total equity, $m | NaN | |||||||||||||||||||||||||
Debt-to-equity ratio | NaN | |||||||||||||||||||||||||
Adjusted equity ratio | NaN | |||||||||||||||||||||||||
CASH FLOW | ||||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
Depreciation, amort., depletion, $m | NaN | |||||||||||||||||||||||||
Funds from operations, $m | NaN | |||||||||||||||||||||||||
Change in working capital, $m | NaN | |||||||||||||||||||||||||
Cash from operations, $m | NaN | |||||||||||||||||||||||||
Maintenance CAPEX, $m | NaN | |||||||||||||||||||||||||
New CAPEX, $m | NaN | |||||||||||||||||||||||||
Total CAPEX, $m | NaN | |||||||||||||||||||||||||
Free cash flow, $m | NaN | |||||||||||||||||||||||||
Issuance/(repurchase) of shares, $m | NaN | |||||||||||||||||||||||||
Retained Cash Flow, $m | NaN | |||||||||||||||||||||||||
Pot'l extraordinary dividend, $m | NaN | |||||||||||||||||||||||||
Cash available for distribution, $m | NaN | |||||||||||||||||||||||||
Discount rate, % | NaN | |||||||||||||||||||||||||
PV of cash for distribution, $m | NaN | |||||||||||||||||||||||||
Current shareholders' claim on cash, % | NaN |